A Dose-Escalation Study with a Special Drug Delivery System (SDS) of BEZ235, a Novel Dual PI3K/mTOR Inhibitor, in Patients with Metastatic/Advanced Solid Tumors

被引：0
|
作者：
Rodon, J.
Infante, J.
Burris, H.
Tabernero, J.
Ranson, M. R.
Rouyrre, N.
Duval, V.
Silva, A.
Hackl, W.
Baselga, J.
机构：
[1] Vail Hebron Univ Hosp, Barcelona, Spain
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] Christie Hosp NHS Trust, Manchester M20 4BX, Lancs, England
[4] Novartis Pharma AG, Basel, Switzerland
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/0008-5472.SABCS10-P6-15-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-15-07
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I Dose-escalation Study of the Oral Dual MTOR/PI3K Inhibitor BEZ235, Solid Dispersion System (SDS) Sachet Formulation, in Patients with Advanced Solid Tumors
    Rodon Ahnert, J.
    Burris, H. A.
    Schellens, J. H. M.
    Schuler, M.
    Goodman, O.
    Britten, C.
    Richards, D.
    Demanse, D.
    Silva, A.
    Baselga, J.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 112 - 112
  • [2] A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors.
    Peyton, J. D.
    Ahnert, J. Rodon
    Burris, H.
    Britten, C.
    Chen, L. C.
    Tabernero, J.
    Duval, V.
    Rouyrre, N.
    Silva, A. P.
    Quadt, C.
    Baselga, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer
    Rodon, Jordi
    Perez-Fidalgo, Alejandro
    Krop, Ian E.
    Burris, Howard
    Guerrero-Zotano, Angel
    Britten, Carolyn D.
    Becerra, Carlos
    Schellens, Jan
    Richards, Donald A.
    Schuler, Martin
    Abu-Khalaf, Maysa
    Johnson, Faye M.
    Ranson, Malcolm
    Edenfield, Jeff
    Silva, Antonio P.
    Hackl, Wolfgang
    Quadt, Cornelia
    Demanse, David
    Duval, Vincent
    Baselga, Jose
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (02) : 285 - 298
  • [4] Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer
    Jordi Rodon
    Alejandro Pérez-Fidalgo
    Ian E. Krop
    Howard Burris
    Angel Guerrero-Zotano
    Carolyn D. Britten
    Carlos Becerra
    Jan Schellens
    Donald A. Richards
    Martin Schuler
    Maysa Abu-Khalaf
    Faye M. Johnson
    Malcolm Ranson
    Jeff Edenfield
    Antonio P. Silva
    Wolfgang Hackl
    Cornelia Quadt
    David Demanse
    Vincent Duval
    Jose Baselga
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 285 - 298
  • [5] The PI3K/mTOR inhibitor BEZ235 given twice daily for the treatment of patients (pts) with advanced solid tumors
    Arkenau, Hendrik-Tobias
    Jones, Suzanne Fields
    Kurkjian, Carla
    Infante, Jeffrey R.
    Pant, Shubham
    Burris, Howard A.
    Moore, Kathleen N.
    McMeekin, D. Scott
    Greco, Frank A.
    Ramsey, Sara
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies
    Wise-Draper, Trisha M.
    Moorthy, Ganesh
    Salkeni, Mohamad A.
    Karim, Nagla Abdel
    Thomas, Hala Elnakat
    Mercer, Carol A.
    Beg, M. Shalaan
    O'Gara, Sue
    Olowokure, Olugbenga
    Fathallah, Hassana
    Kozma, Sara C.
    Thomas, George
    Rixe, Olivier
    Desai, Pankaj
    Morris, John C.
    TARGETED ONCOLOGY, 2017, 12 (03) : 323 - 332
  • [7] A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies
    Trisha M. Wise-Draper
    Ganesh Moorthy
    Mohamad A. Salkeni
    Nagla Abdel Karim
    Hala Elnakat Thomas
    Carol A. Mercer
    M. Shalaan Beg
    Sue O’Gara
    Olugbenga Olowokure
    Hassana Fathallah
    Sara C. Kozma
    George Thomas
    Olivier Rixe
    Pankaj Desai
    John C. Morris
    Targeted Oncology, 2017, 12 : 323 - 332
  • [8] A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors
    Johanna C. Bendell
    Carla Kurkjian
    Jeffrey R. Infante
    Todd M. Bauer
    Howard A. Burris
    F. Anthony Greco
    Kent C. Shih
    Dana S. Thompson
    Cassie M. Lane
    Lindsey H. Finney
    Suzanne F. Jones
    Investigational New Drugs, 2015, 33 : 463 - 471
  • [9] A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors
    Bendell, Johanna C.
    Kurkjian, Carla
    Infante, Jeffrey R.
    Bauer, Todd M.
    Burris, Howard A., III
    Greco, F. Anthony
    Shih, Kent C.
    Thompson, Dana S.
    Lane, Cassie M.
    Finney, Lindsey H.
    Jones, Suzanne F.
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (02) : 463 - 471
  • [10] The Dual PI3K/mTOR Inhibitor BEZ235 Is Effective in Lung Cancer Cell Lines
    Herrera, Vivian Arrias
    Zeindl-Eberhart, Evelyn
    Jung, Andreas
    Huber, Rudolf Maria
    Bergner, Albrecht
    ANTICANCER RESEARCH, 2011, 31 (03) : 849 - 854
12345